Literature DB >> 33420570

[Pulmonary lymphangioleiomyomatosis (LAM)].

D Theegarten1, T Hager2.   

Abstract

Lymphangioleiomyomatosis (LAM) is a rare lung disease that mostly occurs in female patients. A total of 200-400 people are assumed to be infected in Germany. A sporadic form and a form associated with the tuberous sclerosis complex (TSC) can be separated. Mutations of the TSC‑1 and TSC‑2 genes are relevant. Morphologically, pulmonary multicysts and marginal micronodal proliferations of LAM cells are characteristic. Combinations with renal angiomyolipoma are typical and, in cases with TSC glioma, facial angiofibroma and ungual fibroma are seen. Prognosis is favorable (10-year survival: 80%) and with the use of mTORC1 inhibitors it could be improved. Lung transplantation can be considered in some cases.

Entities:  

Keywords:  Lymphangioleiomyomatosis; Renal angiomyolipoma; TSC1 gene; TSC2 gene; Tuberous sclerosis

Year:  2021        PMID: 33420570     DOI: 10.1007/s00292-020-00901-w

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  2 in total

Review 1.  [Lymphangioleiomyomatosis].

Authors:  H Wirtz
Journal:  Zentralbl Chir       Date:  2013-11-25       Impact factor: 0.942

2.  Continuous Positive Airway Pressure Restores Declarative Memory Deficit in Obstructive Sleep Apnea.

Authors:  Ina E Djonlagic; Meng Guo; Moroke Igue; Divya Kishore; Robert Stickgold; Atul Malhotra
Journal:  Am J Respir Crit Care Med       Date:  2021-05-01       Impact factor: 21.405

  2 in total
  2 in total

1.  A pulmonary lymphangioleiomyomatosis with multi-site angiomyolipoma: a case report.

Authors:  Fan He; Jingjiao Zhong; Rong Chai; Jing Sheng; Tiejun Zhao; Yiping Han
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

2.  Physiotherapy in lymphangioleiomyomatosis: a systematic review.

Authors:  Victoria Maria Garcia de Medeiros; Jéssica Gonçalves de Lima; Claudia Rosa; Juliana Rega; Mauro Felippe Felix Mediano; Luiz Fernando Rodrigues Junior
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.